PTWO vs. SHLT, TOI, CRVS, YS, HOOK, PASG, TPST, CNTB, NVNO, and VTVT
Should you be buying Pono Capital Two stock or one of its competitors? The main competitors of Pono Capital Two include SHL Telemedicine (SHLT), Oncology Institute (TOI), Corvus Pharmaceuticals (CRVS), YS Biopharma (YS), Hookipa Pharma (HOOK), Passage Bio (PASG), Tempest Therapeutics (TPST), Connect Biopharma (CNTB), enVVeno Medical (NVNO), and vTv Therapeutics (VTVT). These companies are all part of the "medical" sector.
Pono Capital Two (NASDAQ:PTWO) and SHL Telemedicine (NASDAQ:SHLT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.
Pono Capital Two has higher earnings, but lower revenue than SHL Telemedicine.
60.8% of Pono Capital Two shares are held by institutional investors. Comparatively, 20.1% of SHL Telemedicine shares are held by institutional investors. 63.9% of Pono Capital Two shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
SHL Telemedicine received 1 more outperform votes than Pono Capital Two when rated by MarketBeat users.
In the previous week, Pono Capital Two had 4 more articles in the media than SHL Telemedicine. MarketBeat recorded 5 mentions for Pono Capital Two and 1 mentions for SHL Telemedicine. SHL Telemedicine's average media sentiment score of 1.00 beat Pono Capital Two's score of 0.96 indicating that SHL Telemedicine is being referred to more favorably in the news media.
SHL Telemedicine has a consensus target price of $11.00, suggesting a potential upside of 98.10%. Given SHL Telemedicine's higher probable upside, analysts clearly believe SHL Telemedicine is more favorable than Pono Capital Two.
SHL Telemedicine's return on equity of 0.00% beat Pono Capital Two's return on equity.
Summary
SHL Telemedicine beats Pono Capital Two on 6 of the 11 factors compared between the two stocks.
Get Pono Capital Two News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTWO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTWO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pono Capital Two Competitors List
Related Companies and Tools
